AZD9150, an antisense oligonucleotide containing a restricted ethyl modification targeting STAT3, reduced STAT3 expression in a wide range of preclinical cancer models and showed antitumor activity in lymphoma, neuroblastoma, and lung cancer models [88,89]. The gene discussed is STAT3; the disease is lymphoma.